# Diabetes Research Hub — Automated Iteration Report

**Date:** 2026-08-06 (Thursday)
**Run type:** Daily iteration (not Monday — no weekly PubMed sweep)

## Summary

State-aware run. Corpus stable at **286 papers** (273 VETTED / 13 FLAGGED / 0 UNVETTED). One research path re-validated, credibility sweep clean, full pipeline rebuilt 41/41 [OK].

## Step 1 — Credibility sweep (every run): CLEAN
- Fabricated PMIDs (>=42,000,000) across all scripts: **none**
- "zero SAEs" / "zero rejection" overstatement: **none**
- Preclinical "curative"/"achieves cure" overstatement: **none** (the single "curative" string is inside `verify_before_deploy.py`, which is the detector listing terms to catch — not a violation)

## Step 2 — Path validation: `tacrolimus -> inflammation`
Selected as the stalest **distinct** partially-validated path not covered by a dedicated watch item (last re-validated 2026-07-03; verapamil/tegoprubart/teplizumab paths are each tracked by their own watch items).

**Rating: PARTIALLY_VALIDATED (unchanged) — context-dependent, no promotion.**

Tacrolimus has a genuinely bidirectional effect on inflammation, and the fresh literature reinforces both arms rather than resolving toward one:

- **Anti-inflammatory arm (in T cells):** 2025 narrative review *Clinical applications of tacrolimus in ocular diseases* (PMID **41264132**, Int Ophthalmol 2025) reiterates the FKBP-12 / calcineurin / NFAT-inhibition mechanism suppressing IL-2 and downstream pro-inflammatory cytokines, and modulating the Th1/Th2 and Th17/Treg balance. Complements the prior PLOS One human-T-cell NF-κB finding (PMID 23573283).
- **Pro-inflammatory arm (in vasculature / kidney):** added an **independent second source** — PMID **23958496** (calcineurin inhibitors recruit JAK2/JNK, TLR signaling and the UPR to activate NF-κB-mediated inflammatory responses in kidney tubular cells), complementing the vascular TLR4 finding (PMID 27295076, endothelial/VSMC ROS + NF-κB, abolished in TLR4−/− aortas). The 2025 Pharmacological Reports review of tacrolimus in diabetic rodent models (PMID 39836342) remains consistent with the diabetogenic/pro-inflammatory side.

**Conclusion:** no 2025–26 evidence contradicts the bidirectional picture; net effect is NOT uniformly anti-inflammatory. External PMIDs now: 23573283, 27295076, 39836342, 41264132, 23958496.

## Step 3 — Pipeline rebuild: 41/41 [OK]
`run_quality_improvements.py` completed all 41 stages successfully (dashboards, gap deep-dives, PMID verification, evidence network, corpus/paths dashboards, GitHub Pages rebuild, post-processing).

## Step 4 — State & queue
- Recorded run in `run_history` (now 113 runs).
- Reprioritized the validate_path queue item → next distinct partial to re-validate is **`TXNIP_NLRP3_beta_cell_DKD`** (last 2026-07-16).
- State saved atomically; backup `agent_state.json.bak_2026-08-06` written.

## Known blocker (unchanged — requires user)
Git **push** remains blocked: no GitHub auth in the sandbox (`could not read Username for https://github.com`). All research changes are saved to working files on disk regardless. To sync, run from local PowerShell at `C:\Users\justi\OneDrive\Diabetes_Research`:
```powershell
Remove-Item .git\*.lock -ErrorAction SilentlyContinue
git add -A; git commit -m "Daily iteration 2026-08-06"; git push
```

## Sources
- [Tacrolimus inhibits NF-κB activation in peripheral human T cells (PMID 23573283)](https://pubmed.ncbi.nlm.nih.gov/23573283/)
- [Clinical applications of tacrolimus in ocular diseases — narrative review 2025 (PMID 41264132)](https://pubmed.ncbi.nlm.nih.gov/41264132/)
- [Calcineurin inhibitors induce vascular inflammation via TLR4 signaling (PMID 27295076)](https://pubmed.ncbi.nlm.nih.gov/27295076/)
- [Calcineurin inhibitors recruit JAK2/JNK, TLR signaling, UPR to activate NF-κB in kidney tubular cells (PMID 23958496)](https://pubmed.ncbi.nlm.nih.gov/23958496/)
